*** CHEMICAL IDENTIFICATION *** RTECS NUMBER : BV8152500 CHEMICAL NAME : Androst-4-ene-3,17-dione, 4-hydroxy- CAS REGISTRY NUMBER : 566-48-3 BEILSTEIN REFERENCE NO. : 1889793 LAST UPDATED : 199709 DATA ITEMS CITED : 4 MOLECULAR FORMULA : C19-H26-O3 MOLECULAR WEIGHT : 302.45 WISWESSER LINE NOTATION : L E5 B666 FV OV MUTJ A1 E1 NQ COMPOUND DESCRIPTOR : Reproductive Effector Hormone SYNONYMS/TRADE NAMES : * CGP 32349 * Formestane * 4-Hydroxy-delta(sub 4)-androstenedione * 4-Hydroxy-4-androstene-3,17-dione *** HEALTH HAZARD DATA *** ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE : 182 mg/kg SEX/DURATION : female 3-5 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition REFERENCE : JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939- Volume(issue)/page/year: 118,93,1988 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE : 136 mg/kg SEX/DURATION : female 2-4 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - other effects REFERENCE : JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939- Volume(issue)/page/year: 118,93,1988 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE : 120 mg/kg SEX/DURATION : female 11-22 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - behavioral REFERENCE : ECJPAE Endocrinologia Japonica. (Japan Pub. Trading Co., Ltd., POB 5030, Tokyo International, Tokyo, Japan) V.1- 1954- Volume(issue)/page/year: 36,29,1989 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - rat DOSE : 250 mg/kg SEX/DURATION : female 3-7 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) REFERENCE : ENDOAO Endocrinology (Baltimore). (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21203) V.1- 1917- Volume(issue)/page/year: 100,1684,1977 *** END OF RECORD ***